The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.

The invention provides a device and method for the real-time detection of aeropathogens. The device includes an aerosampler having an air inlet and at least one collector tube, a microfluidic system which includes a container, piping, a micro pump for flowing a liquid and a viral detection chamber. The viral detection chamber has an electrode which may be equipped with functionalized bio sensors, a counter electrode, an electronic detection system connectable to the electrodes of the viral detection chamber, and an embedded electronic processing system for processing data from the electronic detection system.

Methods for determination of risk, previous history and/or presence of a betaretrovirus infection in a subject are described herein. Said methods may comprise incubating a biological sample from the subject, the biological sample comprising immune effector-producing cells, with one or more betaretrovirus-specific epitopes, the betaretrovirus-specific epitopes comprising at least 7 contiguous amino acids according to any one of SEQ ID Nos. 1-36, and measuring the production of immune effectors by the immune effector-producing cells, wherein production of the immune effectors by the immune effector-producing cells determines risk and/or presence of betaretrovirus infection in the subject. Isolated peptides and kits for carrying out the methods are also described.

This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.

The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.

The present disclosure is directed to antibodies binding to and neutralizing tire coronavirus designated SARS-CoV-2 and methods for use thereof.

A test device by immunochromatography comprises a case including a dropping window for a specimen and a detection window, and a test piece in the case. The test piece includes first and second detection portions, and a dropping area common to the first and second detection portions. When the specimen is dropped on the dropping area through the dropping window, the specimen migrates downstream and the same specimen reaches the first and second detection portions. The first detection portion traps a complex of a first labeled body and a first antibody contained in the specimen. The second detection portion traps a complex of a second labeled body and a second antibody contained in the specimen. The first antibody is produced by vaccination or infection with a predetermined virus. The second antibody is produced by infection with the virus. Thus, a test result from each of the first and second detection portions, both visually observed through the detection window, can be determined in parallel and at the same time.

A lateral flow assay device for detection of an analyte in a sample and a method of detection thereof is provided. A quantitative assay for detection of an analyte in a sample is provided. A conjugate is provided. A method of diagnosing COVID 19 in a patient is provided.

The disclosure provides methods for analyzing Adeno-Associated Vims (AAV) vectors. More particularly, the disclosure relates to capillary electrophoresis methods for separating, characterizing, and quantifying AAV vectors as having a full length exogenous polynucleotide, having an exogenous polynucleotide fragment, or lacking any exogenous polynucleotide. In one method, the analysis uses capillary isoelectric focusing (cIEF) on a sample comprising viral vectors containing exogenous polynucleotide under conditions and for a duration sufficient to separate the viral vectors based on the isoelectric point (pI) of each viral vector.

The present application discloses an antigenic detector, including: a pen holder and a pen cap. The pen holder includes: a test paper tube, a test paper assembled in the test paper tube, a test paper support, and a foam support installed on the front end of the test paper tube with a foam and a protective cover; the pen cap includes: a base, an aluminum foil assembled in the base, and an interior of the base forms a cavity into which a front end of the pen holder is inserted, and a reaction solution is sealed inside the cavity of the base by the aluminum foil; the protective cover is detachably installed on the front end of the test paper tube and covers the foam; the foam support is provided with a channel that communicates with an interior of the test paper tube.